Characterization of Reverse Transcriptase Activity and Susceptibility to Other Nucleosides of AZT‐Resistant Variants of HIV‐1
Authors:
- 17 December 1990
- journal article
- clinical trial
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 616 (1) , 346-355
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Nature, time course and dose dependence of zidovudine-related side effectsAIDS, 1989
- Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity.Proceedings of the National Academy of Sciences, 1989
- Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapyAIDS, 1989
- Susceptibility to AZT of HIV-l Variants Grown in Epstein-Barr Virus-Transformed B Cell LinesThe Journal of Infectious Diseases, 1989
- HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged TherapyScience, 1989
- Cessation of zidovudine therapy may lead to increased replication of HIV-11989
- RESUMPTION OF HIV ANTIGEN PRODUCTION DURING CONTINUOUS ZIDOVUDINE TREATMENTThe Lancet, 1988
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro.Proceedings of the National Academy of Sciences, 1987
- ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEXThe Lancet, 1986